Search
Tetracosactide
go.drugbank.com/drugs/DB01284ApprovedInvestigationalTetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. … The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalIt is available as intramuscular or intravenous injections. … L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Products: LEUNASE FOR INJECTION 10,000 iu/vial, LEUNASE ENJEKTABL 10.000 IU FLAKON, 1 ADETCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigationalBacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding … [L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of
Perflenapent
go.drugbank.com/drugs/DB11625ApprovedInvestigationalWithdrawnDodecafluoropentane is also known as perfluoropentane or perflenapent.
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsFidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births … Current available treatments include substitution therapy involving the intravenous administration of standard factor IX once a week for bleeding or as prophylaxis and 2–3 times a week for severe hemophilia
Anidulafungin
go.drugbank.com/drugs/DB00362ApprovedAnidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. … There is preliminary evidence that it has a similar safety profile to caspofungin.
Products: GIXOFU 100 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLEDornase alfa
go.drugbank.com/drugs/DB00003ApprovedInvestigationalDornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. … The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme.
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Conventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. … [A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Categories: Drugs for Treatment of Bone Diseases, Phospholipases A, antagonists & inhibitors